Skip to Main Content

Good morning. Elizabeth Cooney here again in Boston, filling in for Ed Silverman while he takes a summer break. As he would no doubt remind us, we’ve made it to the middle of the week, so why not carry on? We have some news to get you going:

Novartis CEO Vas Narasimhan began his tenure with an inherited scandal. Now he’s got one all his own, STAT says. At issue is what Novartis knew — and when it knew — about the manipulation of data used to win approval of its gene therapy for spinal muscular atrophy.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!